Olopatadine Hydrochloride Ophthalmic Solution is indicated for the treatment of ocular itching associated with allergic ...

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product ...

RVL Pharmaceuticals, Inc. and its affiliates (together, "RVL") announces Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing ...

Launched VIZZ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net pr ...

Opus Genetics (IRD) highlighted its progress achieved during 2025 and upcoming catalysts in 2026. OPGx-BEST1: First ...

Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ...

OSN Cornea/External Disease Board Member Eric D. Donnenfeld, MD, and a panel of experts examined a series of unusual ...

The approval is for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is therapeutically equivalent to Alcon Laboratories’ Pataday ...

Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZ ...

Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials ...

LAHORE: The Punjab government has ordered the immediate withdrawal of several medicines from the market after they were found ...

Okyo Pharma appointed Robert J. Dempsey to serve as the company’s next CEO, according to a press release.